Annual SG&A
$44.86 M
-$16.08 M-26.39%
31 December 2023
Summary:
Y-mAbs Therapeutics annual selling, general & administrative expenses is currently $44.86 million, with the most recent change of -$16.08 million (-26.39%) on 31 December 2023. During the last 3 years, it has risen by +$71.00 thousand (+0.16%). YMAB annual SG&A is now -26.39% below its all-time high of $60.94 million, reached on 31 December 2022.YMAB Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$13.61 M
-$3.62 M-21.00%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly selling, general & administrative expenses is currently $13.61 million, with the most recent change of -$3.62 million (-21.00%) on 30 September 2024. Over the past year, it has increased by +$3.41 million (+33.46%). YMAB quarterly SG&A is now -41.02% below its all-time high of $23.08 million, reached on 30 June 2022.YMAB Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.88 B
-$23.86 M-1.29%
30 September 2024
Summary:
Y-mAbs Therapeutics TTM selling, general & administrative expenses is currently -$1.88 billion, with the most recent change of -$23.86 million (-1.29%) on 30 September 2024. Over the past year, it has dropped by -$1.92 billion (-4312.75%). YMAB TTM SG&A is now -4412.07% below its all-time high of $65.65 million, reached on 30 June 2022.YMAB TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -26.4% | +33.5% | -4312.8% |
| 3 y3 years | +0.2% | -2.7% | -3568.7% |
| 5 y5 years | +400.6% | +189.7% | -10000.0% |
YMAB Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -26.4% | +0.2% | -41.0% | +33.5% | -68.1% | at low |
| 5 y | 5 years | -26.4% | +400.6% | -41.0% | +189.7% | -319.4% | at low |
| alltime | all time | -26.4% | +1308.8% | -41.0% | +1677.2% | -4412.1% | at low |
Y-mAbs Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.61 M(-21.0%) | $53.41 M(+6.8%) |
| June 2024 | - | $17.23 M(+50.8%) | $49.99 M(+13.5%) |
| Mar 2024 | - | $11.43 M(+2.6%) | $44.03 M(-1.8%) |
| Dec 2023 | $44.86 M(-26.4%) | $11.13 M(+9.2%) | $44.86 M(+0.8%) |
| Sept 2023 | - | $10.20 M(-9.5%) | $44.51 M(-7.1%) |
| June 2023 | - | $11.27 M(-8.0%) | $47.94 M(-19.8%) |
| Mar 2023 | - | $12.25 M(+13.5%) | $59.75 M(-1.9%) |
| Dec 2022 | $60.94 M(+11.7%) | $10.79 M(-20.8%) | $60.94 M(-6.7%) |
| Sept 2022 | - | $13.63 M(-41.0%) | $65.28 M(-0.6%) |
| June 2022 | - | $23.08 M(+71.8%) | $65.65 M(+17.1%) |
| Mar 2022 | - | $13.44 M(-11.2%) | $56.04 M(+2.7%) |
| Dec 2021 | $54.57 M(+21.9%) | $15.14 M(+8.2%) | $54.57 M(+0.9%) |
| Sept 2021 | - | $13.99 M(+3.8%) | $54.06 M(+4.5%) |
| June 2021 | - | $13.47 M(+12.6%) | $51.71 M(+6.3%) |
| Mar 2021 | - | $11.97 M(-18.2%) | $48.63 M(+8.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $44.78 M(+129.5%) | $14.63 M(+25.7%) | $44.78 M(+20.8%) |
| Sept 2020 | - | $11.64 M(+12.0%) | $37.09 M(+23.0%) |
| June 2020 | - | $10.39 M(+27.9%) | $30.15 M(+26.2%) |
| Mar 2020 | - | $8.13 M(+17.2%) | $23.89 M(+22.5%) |
| Dec 2019 | $19.51 M(+117.7%) | $6.93 M(+47.5%) | $19.51 M(+24.9%) |
| Sept 2019 | - | $4.70 M(+13.5%) | $15.62 M(+14.8%) |
| June 2019 | - | $4.14 M(+10.6%) | $13.60 M(+19.0%) |
| Mar 2019 | - | $3.74 M(+23.2%) | $11.43 M(+27.5%) |
| Dec 2018 | $8.96 M(+81.5%) | $3.04 M(+13.2%) | $8.96 M(+4.5%) |
| Sept 2018 | - | $2.68 M(+36.6%) | $8.57 M(+28.8%) |
| June 2018 | - | $1.97 M(+54.1%) | $6.66 M(+41.9%) |
| Mar 2018 | - | $1.27 M(-51.9%) | $4.69 M(+37.3%) |
| Dec 2017 | $4.94 M(+55.1%) | $2.65 M(+246.0%) | $3.42 M(+346.0%) |
| Sept 2017 | - | $766.00 K | $766.00 K |
| Dec 2016 | $3.18 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual SG&A year-on-year change?
- What is Y-mAbs Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly SG&A year-on-year change?
- What is Y-mAbs Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM SG&A year-on-year change?
What is Y-mAbs Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of YMAB is $44.86 M
What is the all time high annual SG&A for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual selling, general & administrative expenses is $60.94 M
What is Y-mAbs Therapeutics annual SG&A year-on-year change?
Over the past year, YMAB annual selling, general & administrative expenses has changed by -$16.08 M (-26.39%)
What is Y-mAbs Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of YMAB is $13.61 M
What is the all time high quarterly SG&A for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly selling, general & administrative expenses is $23.08 M
What is Y-mAbs Therapeutics quarterly SG&A year-on-year change?
Over the past year, YMAB quarterly selling, general & administrative expenses has changed by +$3.41 M (+33.46%)
What is Y-mAbs Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of YMAB is -$1.88 B
What is the all time high TTM SG&A for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM selling, general & administrative expenses is $65.65 M
What is Y-mAbs Therapeutics TTM SG&A year-on-year change?
Over the past year, YMAB TTM selling, general & administrative expenses has changed by -$1.92 B (-4312.75%)